A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system

Human Reproduction

Volumn 21, Issue 5, 2006, Pages 1316-1319

  Bahamondes, Luis ^a,b   Espejo Arce, Ximena ^a   Hidalgo, Maria M ^a   Hidalgo Regina, Creusa ^a   Teatin Juliato, Cássia ^a   Petta, Carlos A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Bone mineral density; Contraception; Levonorgestrel releasing intrauterine system; Mirena

Indexed keywords

ESTRADIOL; LEVONORGESTREL;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CONTRACEPTION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; FEMALE; FOREARM; HUMAN; INTERMETHOD COMPARISON; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; PATIENT SELECTION; RADIUS; ULNA;

EID: 33645818163     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei457     Document Type: Article

References (40)

1. Armitage P (1971) Statistical Methods in Medical Research, 3rd edn. A Halsted Press Book, John Wiley and Sons, New York.
2. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA and Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study. Bone 34,728-735.
3. Bahamondes L, Perrotti M, Castro S, Faúndes D, Petta C and Bedone A (1999) Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 71,849-852.
4. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, Diaz J and Faúndes A (2000) The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62,23-27.
5. Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X and Monteiro-Dantas C (2003) Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J Reprod Med 48,637-640.
6. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, dos Santos Fernandes AM, Lui-Filho JF, Perrotti M and Petta CA. A prospective study of the forearm bone density of users of etonorgeotrel- and levonorgeotrel-releasing contraceptive implants. Hum Reprod. Advance Access published October 10, 2005, 10.1093/humrep/dei358.
7. Barbosa I, Olsson SE, Odlind V, Goncalves T and Coutinho E (1995) Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 11,85-95.
8. Chetkowski R, Meldrum D, Steingold K, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP and Judd HL (1986) Biologic effects of transdermal estradiol. N Engl J Med 314,1615-1620.
9. Cromer BA, Blair JM, Mahan JD, Zibners L and Naumovski Z (1996) A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatrics 129,671-676.
10. Cundy T, Evans MC, Roberts H, Wattie D, Ames R and Reid IR (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 303,13-16.
11. Cundy T, Cornish J, Evans M, Roberts H, Elder H and Reid I (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92,569-573.
12. Diaz S, Pavez M, Miranda P, Robertson DN, Sivin I and Croxatto HB (1982) A five-year clinical trial of levonorgestrel Silastic implants (Norplant). Contraception 25,447-456.
13. Diaz S, Pavez M, Miranda P, Johansson EDB and Croxatto HB (1987) Long-term follow-up of women treated with Norplant implants. Contraception 35,551-567.
14. Diaz S, Reyes MV, Zepeda A, Gonzalez GB, Lopez JM, Campino C and Croxatto HB (1999) Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod 4,2499-2505.
15. Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo MM and Arce XE (2000) Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 62,59-61.
16. Gbolade B, Ellis S, Murby B, Randall S and Kirkman R (1998) Bone density in long-term users of depot medroxyprogesterone acetate. BJOG 105,790-794.
17. Hampton NRE, Rees MCP, Lowe DG, Rauramo I, Barlow D and Guillebaud J (2005) Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: A successful regimen for HRT in perimenopausal women. Hum Reprod 20,2653-2660.
18. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C and Petta C (2002) Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 65,129-132.
19. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M and Paavonen J (2004) Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. JAMA 291,1456-1463.
20. Jia MC, Zhou LY, Dong L and Xiao B (1992) Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept 8,33-40.
21. Kaunitz AM (2005) Depo-Provera's black box: Time to reconsider? Contraception 72,165-167.
22. Lockhat FB, Emembolu JO and Konje JC (2005) The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (Levonorgestrel): A 3 year follow-up. Hum Reprod 20,789-793.
23. Luukkainen T, Lähteenmäki P and Toivonen J (1990) Levonorgestrel-releasing intrauterine device. Ann Med 22,85-90.
24. Marshall D, Johnell O and Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312,1254-1259.
25. Monteiro I, Bahamondes L, Diaz J, Perrotti M and Petta C (2002) Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: A pilot study. Contraception 65,325-328.
26. Naessen T, Olsson SE and Gudmundson J (1995) Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52,35-39.
27. Nilsson G, Haukkamaa M, Vierola H and Luukkainen T (1982) Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 17,529-536.
28. Nilsson CG, Lahteenmaki PL and Luukkainen T (1984) Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 41,52-55.
29. Perrotti M, Bahamondes L, Petta C and Castro S (2001) Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 76,469-473.
30. Petitti DB, Piaggio G, Metha S, Cravioto MC and Meirik O (2000) Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. Obstet Gynecol 95,736-744.
31. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E, Silva JC, Podgaec S and Bahamondes L (2005) Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 20,1993-1998.
32. Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA and Laatikainen TJ (1995) Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol 172,114-119.
33. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F and Laatikainen T (2002) Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: Clinical, endometrial and metabolic response. BJOG 109,136-144.
34. Robertson DN, Sivin I, Nash HA, Braun J and Dinh J (1983) Release rates of levonorgestrel from Silastic capsules, homogeneous rods and covered rods in humans. Contraception 27,483-495.
35. Ronnerdag M and Odlind V (1999) Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 78,716-721.
36. United States Food and Drug Administration. Talk Paper Black Box Warning Added Concerning Long-Term Use of Depo-Provera Contraceptive Injection, November 17, 2004.
37. Volpe A, Amram A, Cagnacci A and Battaglia C (1997) Biochemical aspects of hormonal contraceptive: Effects on bone metabolism. Eur J Contracept Reprod Health Care 2,123-126.
38. World Health Organization. WHO Statement on Hormonal Contraception and Bone Health, July, 2005.
39. World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Post-Menopausal Osteoporosis. Report of a WHO Study Group. WHO, Geneva (WHO technical report Series 843).
40. World Health Organization (2004) Medical Eligibility Criteria for Contraceptive Use, 3rd edn. WHO, Geneva.